CClinicalTrials.gg
TerminatedNCT00243828Updated Sep 15, 2015

Assessment of the Effectivity of Total-face Mask for Noninvasive Ventilation During Acute Respiratory Failure

A Phase 4 interventional study of Total Face Mask in Respiratory Insufficiency, sponsored by Corporacion Parc Tauli. Terminated at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-15.

Sponsored by Corporacion Parc Tauli · Phase 4, Interventional, and Treatment

Why this study was terminated
Very low rate of recruitment anticipated futility of pursuing the study
Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Total-face mask may improve the efficacy of NIV compared to conventional face mask in patients with acute respiratory failure due to enhanced tolerance and the allowance of higher airway pressure without massive leaks.MAIN OBJECTIVE: To assess, in acute respiratory failure patients, whether the total-face mask reduce the intubation rate. METHODS: 300 patients admitted in the ICU for acute respiratory failure needing continuous noninvasive mechanical ventilation. The type of mask (total-face vs. conventional face mask) will be randomized. Defined failure criteria and weaning technique will be used.

Read the detailed description

HYPOTESIS: Total-face mask may improve the efficacy of NIV compared to conventional face mask in patients with acute respiratory failure due to enhanced tolerance and the allowance of higher airway pressure without massive leaks.OBJECTIVES: To assess, in acute respiratory failure patients, whether the total-face mask reduce the intubation rate. Additionally, whether it may improve mask tolerance, skin pressure damage, number of patients receiving higher pressures, or even a reduction in mortality. METHODS: 300 patients admitted in the ICU for acute respiratory failure needing continuous noninvasive mechanical ventilation. The type of mask (total-face vs. conventional face mask) will be randomized. PEEp will be titrated to the best oxygenation and IPAP up to reduce dyspnea and respiratory frequency, with the limits at clinical tolerance and massive leaks. Defined failure criteria and weaning technique will be used. Data to record include clinical parameters and mortality risk score (SAPS II), and physiologic response to NIV (either subjective and objective), technique failures and outcome. EXPECTED RESULTS: The study has been powered to detect a 30% relative improvement in intubation rate from a 35% baseline incidence of intubation in the conventional group.

02

Conditions studied

  • Respiratory Insufficiency

Keywords

  • Noninvasive Mechanical Ventilation
  • Acute Respiratory Failure
  • Intubation
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's enrollment of 300 is above the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Corporacion Parc Tauli is the lead sponsor of 163 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Acute Hypoxemia:PaO2/FiO2 lower than 200 mmHg
  • Respiratory rate greater than 30 breaths/min

Exclusion criteria

Exclusion Criteria:

  • cardiogenic lung edema
  • COPD exacerbation
  • Low level of consciousness (GCS \< 13)
  • Hemodynamic instability
  • Facial damage
  • Do-not-intubate orders
  • Lack of informed consent
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants

Interventions

  • DeviceTotal Face Mask
06

What researchers measure

Primary outcomes

  1. Intubation rate

Secondary outcomes

  1. Hospital survival

07

Study locations

1 site
  • Hospital de Sabadell
    Sabadell, Barcelona 08208, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00243828
Lead sponsor
Corporacion Parc Tauli
First posted
Oct 25, 2005
Start date
Nov 2005
Primary completion
Sep 2007
Completion
Dec 2007
Last update
Sep 15, 2015

Study contacts

Rafael Fernandez, MD, PhD
study director · Corporacion Parc Tauli

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion